Gentile Vincenzo, Antonini Gabriele, Antonella Bertozzi Maria, Dinelli Nicola, Rizzo Cosimo, Ashraf Virmani Mohamed, Koverech Aleardo
Dipartimento di Urologia U Bracci, Sapienza University of Rome, Italy.
Curr Med Res Opin. 2009 Sep;25(9):2223-8. doi: 10.1185/03007990903138416.
The association of diabetes-related vascular damage and the role of metabolic factors in erectile dysfunction are well known in the literature. The compounds propionyl-L-carnitine (PLC), L-arginine (L-Arg) and nicotinic acid have numerous metabolic actions which have been reported to improve endothelial function. This study investigated the administration of the combination of these three compounds alone and in association with an inhibitor of 5-phosphodiesterase (5PDE), vardenafil, on endothelial function in diabetic patients with erectile dysfunction.
A total of 40 patients aged between 50 and 60 years with insulin-dependent diabetes (IDDM) for 3-4 years were selected from 509 patients presenting with erectile dysfunction. The patients were randomly subdivided into four groups of ten to be treated for 12 weeks. Group A was administered one sachet each day of test formulation containing PLC, L-Arg and nicotinic acid (Ezerex); group B with one 20 mg capsule of vardenafil (Levitra) twice a week; group C was treated with one sachet each day of the test formulation plus vardenafil 20 mg twice a week. Group D was administered placebo capsules twice weekly. Endothelial function was evaluated by examining flow-mediated dilation (FMD) and erectile function was estimated with the International Index of Erectile Function (IIEF5) questionnaire in all subjects.
At the end of treatment group A showed an increment of 2 points in the IIEF5; group B showed an increment of 4 points; group C, the group which was administered all the treatments, showed an increment of 5 points, and group D, treated with placebo, showed no increment in the IIEF5.
Although there was a small number of subjects in this study the data suggest that the test formulation may improve the endothelial situation in diabetes. The test formulation together with vardenafil was better than the 5PDE inhibitor alone, but further studies are needed to confirm these findings.
糖尿病相关血管损伤与代谢因素在勃起功能障碍中的作用在文献中已广为人知。化合物丙酰-L-肉碱(PLC)、L-精氨酸(L-Arg)和烟酸具有多种代谢作用,据报道可改善内皮功能。本研究调查了单独使用这三种化合物的组合以及与5-磷酸二酯酶(5PDE)抑制剂伐地那非联合使用对糖尿病勃起功能障碍患者内皮功能的影响。
从509例勃起功能障碍患者中选取40例年龄在50至60岁之间、胰岛素依赖型糖尿病(IDDM)病程为3至4年的患者。将患者随机分为四组,每组10人,治疗12周。A组每天服用一袋含有PLC、L-Arg和烟酸的试验制剂(Ezerex);B组每周两次服用一粒20毫克的伐地那非胶囊(Levitra);C组每天服用一袋试验制剂加每周两次20毫克伐地那非。D组每周两次服用安慰剂胶囊。通过检测血流介导的血管舒张(FMD)评估内皮功能,并用国际勃起功能指数(IIEF5)问卷评估所有受试者的勃起功能。
治疗结束时,A组IIEF5增加2分;B组增加4分;接受所有治疗的C组增加5分,而接受安慰剂治疗的D组IIEF5无增加。
尽管本研究中的受试者数量较少,但数据表明试验制剂可能改善糖尿病患者的内皮状况。试验制剂与伐地那非联合使用比单独使用5PDE抑制剂效果更好,但需要进一步研究来证实这些发现。